Home » Stocks » GW Pharmaceuticals

GW Pharmaceuticals PLC (GWPH)

Stock Price: $135.37 USD 2.50 (1.88%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.20B
Revenue (ttm) 392.72M
Net Income (ttm) 33.08M
Shares Out 31.08M
EPS (ttm) 1.07
PE Ratio 126.51
Forward PE 136.99
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $135.37
Previous Close $132.87
Change ($) 2.50
Change (%) 1.88%
Day's Open 133.31
Day's Range 132.00 - 135.37
Day's Volume 260,199
52-Week Range 67.98 - 175.35

More Stats

Market Cap 4.20B
Enterprise Value 3.73B
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 31.08M
Float 30.36M
EPS (basic) 0.011
EPS (diluted) 1.07
FCF / Share -0.74
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.79%
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.39M
Short Ratio 15.67
Short % of Float n/a
Beta 1.94
PE Ratio 126.51
Forward PE 136.99
P/FCF Ratio n/a
PS Ratio 10.70
PB Ratio 5.64
Revenue 392.72M
Operating Income -74.28M
Net Income 33.08M
Free Cash Flow -23.07M
Net Cash 475.75M
Net Cash / Share 15.33
Gross Margin 72.35%
Operating Margin -18.91%
Profit Margin 8.40%
FCF Margin -5.87%
ROA -5.79%
ROE 4.88%
ROIC 15.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 15
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(40.73% upside)
Current: $135.37
Target: 190.50
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth2344.31%47.61%-32.22%-
Gross Profit2846.754.118.91
Operating Income-118-289-166-129
Net Income-9.02-295-170-91.70
Shares Outstanding372334306272
Earnings Per Share--0.11-0.07-0.04
Operating Cash Flow-123-232-149-120
Capital Expenditures61.63-32.89-20.10-12.91
Free Cash Flow-61.84-265-169-133
Cash & Equivalents5373553220.00
Total Debt27.225.916.35-
Net Cash / Debt5103493160.00
Book Value726415381-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name GW Pharmaceuticals PLC
Country United Kingdom
Employees 901
CEO Justin D. Gover

Stock Information

Ticker Symbol GWPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: GWPH
IPO Date May 1, 2013


GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.